Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Hendra_virus
|
| gptkbp:appointed_by |
gptkb:horse_race
|
| gptkbp:approves |
gptkb:2012
gptkb:Australia |
| gptkbp:category |
preventive vaccine
|
| gptkbp:clinical_trial |
conducted
prevention of Hendra virus infection |
| gptkbp:contraindication |
none known
|
| gptkbp:developed_by |
gptkb:Zoetis
|
| gptkbp:dosage_form |
1 m L
|
| gptkbp:formulation |
injection
|
| gptkbp:frequency |
gptkb:annually
|
| gptkbp:healthcare |
important for equine and human health
|
| https://www.w3.org/2000/01/rdf-schema#label |
Equivac He V
|
| gptkbp:hunting_technique |
in endemic areas
|
| gptkbp:is_effective_against |
high
peer-reviewed |
| gptkbp:is_vulnerable_to |
gptkb:educational_campaigns
ongoing government and private sectors refrigerated veterinary clinics varies by provider ongoing research involves local stakeholders based on research between government and industry based on risk assessment advancements in veterinary medicine trained personnel required inactivated virus contributes to global disease control post-vaccination observation recommended reduces Hendra virus outbreaks reduces risk of disease by Australian Pesticides and Veterinary Medicines Authority |
| gptkbp:label |
contains instructions
|
| gptkbp:legislation |
mandatory in some regions
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:manufacturer |
gptkb:Zoetis_Australia_Pty_Ltd.
|
| gptkbp:moral |
considerations in development
|
| gptkbp:regulatory_compliance |
registered
|
| gptkbp:requires |
gptkb:battle
|
| gptkbp:research_areas |
collaborative efforts
|
| gptkbp:safety_features |
generally safe
|
| gptkbp:shelf_life |
2 years
|
| gptkbp:side_effect |
rare
mild swelling |
| gptkbp:storage |
2-8° C
|
| gptkbp:targets |
gptkb:Equus_caballus
gptkb:Hendra_virus |
| gptkbp:type |
equine vaccine
|